Belatacept Therapy for the Failing Renal Allograft
Status:
Completed
Trial end date:
2019-12-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and effectiveness of belatacept (Nulojix®) in
preventing antibody formation in patients with chronic failing kidney transplants. This study
is a randomized study of first-time kidney transplant patients who have worsening kidney
function and biopsy proven grade 2 or 3 interstitial fibrosis/tubular atrophy (IF/TA).
Patients must be eligible to get a second transplant. They must have completed or be actively
undergoing evaluation for re-listing for a second transplant. Patients will be randomized to
either convert to belatacept or continue on calcineurin inhibitor-based therapy.